Breaks Categories: Stock Spotlights

ThursdaySep 10, 2026 1:10 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer, taking responsibility for advancing the company’s proprietary BiTAC(R) technology and broader oncology pipeline toward clinical development. The company’s lead BiTAC-TCE program uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s Paul-Ehrlich-Institute provided additional clarity around the program’s proposed non-clinical development strategy, while preclinical data presented at the AACR Annual Meeting showed selective activity against cells expressing both target molecules. Beyond BiTAC, VERAXA is developing bispecific antibody-drug…

Continue Reading

ThursdaySep 10, 2026 12:22 pm

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations. In FY2026, ETST reported revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024, while also reporting positive operating cash flow and a stronger balance sheet. The company reduced total liabilities from $3.146…

Continue Reading

WednesdaySep 02, 2026 3:44 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care

Regentis Biomaterials (NYSE American: RGNT) is advancing a regenerative approach to cartilage repair with GelrinC, a cell-free, off-the-shelf hydrogel implant designed to create a temporary environment that supports the body’s natural ability to regenerate damaged knee cartilage. Unlike conventional implants that primarily replace or reinforce damaged tissue, GelrinC is injected into a cartilage lesion and cured in place with ultraviolet light before gradually degrading as new tissue develops. The company reports encouraging clinical results, including greater pain improvement versus microfracture at two years and MRI evidence of cartilage regeneration. GelrinC already has CE Mark approval in Europe, where Regentis is preparing for…

Continue Reading

ThursdayAug 27, 2026 3:41 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug development increasingly expands beyond controlling inflammation toward neuroprotection and myelin preservation. Preclinical studies demonstrated myelin preservation and functional recovery in animal models, while the company’s Phase 1 program generated safety and pharmacokinetic data supporting further development. The U.S.…

Continue Reading

ThursdayAug 27, 2026 3:12 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical and European commercial tracks, with more than half of the 80-patient pivotal Phase III SAGE study enrolled and recruitment targeted for completion in the third quarter of 2026. The FDA-approved single-arm study uses a historical microfracture control dataset owned by Regentis, and the company reports that the first 40 enrolled patients closely match the historical control group in baseline characteristics. In Europe, where GelrinC already has CE Mark approval, Regentis is preparing for broader commercialization through surgeon training, an expanding network of Centers of Excellence…

Continue Reading

ThursdayAug 27, 2026 2:32 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Marks Growth as Avenvi Expands Asset Base

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its strengthened position among OTC-listed companies through consistent financial growth, timely reporting, vertical integration, prudent capital allocation, and ownership of hard real estate assets. Revenue increased to $35.7 million in FY2026 from $33.1 million in FY2025 and $11.95 million in FY2024, while gross profit rose to $25.5 million from $24.3 million and $7.8 million. The company attributes this progress to strategic investments and acquisitions made without adding debt, particularly its purchase of Avenvi, a real estate company whose 13-property portfolio includes the Texas property housing ETST’s Mister Meds…

Continue Reading

WednesdayAug 19, 2026 1:04 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS around the idea that multiple sclerosis disability can progress independently of relapses, known as progression independent of relapse activity (“PIRA”). A recent article discusses chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system as potential contributors to ongoing tissue damage that may not be adequately addressed by therapies focused primarily on peripheral immune activity. Lucid-MS takes a different approach by targeting myelin degradation, with the goal of preserving myelin and supporting functional recovery rather than broadly…

Continue Reading

TuesdayAug 18, 2026 1:54 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing

Regentis Biomaterials (NYSE American: RGNT) is strengthening the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair technology as it moves toward broader commercialization. The company recently received a Japanese Notice of Allowance for patent protection covering the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC. This followed a recent U.S. issuance that expanded its global IP portfolio to nearly 30 patents. Regentis’ proprietary manufacturing process increases yield fivefold, simplifies production and is built to support commercial-scale manufacturing—important advantages for an off-the-shelf cartilage-repair product designed to avoid the complexity and cost of cell-based procedures. The milestone comes as the company…

Continue Reading

TuesdayAug 18, 2026 12:59 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology

VERAXA Biotech (NASDAQ: VRXA) was featured in a recent article highlighting how its collaboration with AI-focused research organization Ardigen could strengthen the company’s oncology pipeline as artificial intelligence plays an increasingly important role in drug discovery. By combining Ardigen’s expertise in AI, computational biology and bioinformatics with VERAXA’s proprietary BiTAC(R) platform, the companies aim to use AI to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while improving target validation and reducing development risks. VERAXA’s “AND-gated” approach, which activates therapies only when two cancer-associated targets are present on the same cell, may be particularly well suited to AI-driven analysis…

Continue Reading

FridayAug 14, 2026 3:07 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Builds Foundation for Biomarker-Driven Cancer Therapy

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its precision oncology strategy through ONC010, a nanoparticle-encapsulated PNKP inhibitor being developed for biomarker-selected cancers. The company is building the manufacturing and scientific foundation needed to advance the program toward first-in-human studies, including polymer process development and analytical characterization activities with Nanosoft Polymers and metabolism studies through Nucro-Technics as part of its IND-enabling program. These efforts are designed to support scalable manufacturing, characterize ONC010’s metabolic profile and generate data for future pharmacokinetic, toxicology and regulatory activities. By combining targeted PNKP inhibition, nanoparticle…

Continue Reading